Bile acids in human plasma interfere with cholecystokinin bioassay using dispersed pancreatic acini
- PMID: 1995267
- DOI: 10.1007/BF01318202
Bile acids in human plasma interfere with cholecystokinin bioassay using dispersed pancreatic acini
Abstract
A bioassay using dispersed pancreatic acini was used to measure fasting plasma cholecystokinin (CCK) concentrations in 105 patients with various kinds of gastrointestinal diseases, 17 patients with diabetes mellitus, and 6 healthy volunteers. High plasma CCK bioactivities were observed in patients with obstructive jaundice, choledocolithiasis, and primary biliary cirrhosis. Twenty-three samples with high CCK bioactivities were assayed by the same bioassay after the addition of a specific CCK antagonist and by a CCK radioimmunoassay in order to determine whether the high CCK-like bioactivity was due to circulating CCK or other factors. High CCK bioactivities were partially inhibited by the specific CCK antagonist, CR-1409, but the activities were not totally abolished. The residual bioactivities (not inhibited by CR-1409) correlated with plasma bile acid concentrations. The inhibitable CCK bioactivities correlated with plasma CCK levels obtained by radioimmunoassay. Although the bioassay using dispersed pancreatic acini has several advantages for measuring plasma CCK, this method overestimates CCK bioactivities in patients with high plasma bile acid concentrations.
Similar articles
-
[Basal plasma cholecystokinin levels in digestive diseases--comparison between CCK-8 like bioactivity by bioassay and CCK immunoreactivity by radioimmunoassay].Nihon Shokakibyo Gakkai Zasshi. 1989 Nov;86(11):2572-8. Nihon Shokakibyo Gakkai Zasshi. 1989. PMID: 2601119 Japanese.
-
Determination of plasma cholecystokinin (CCK) concentrations by bioassay and radioimmunoassay in man. A critical evaluation.Regul Pept. 1992 Feb 18;37(3):255-69. doi: 10.1016/0167-0115(92)90619-6. Regul Pept. 1992. PMID: 1557514
-
Cholecystokinin receptor antagonist loxiglumide: influence on bilio-pancreatic secretion and gastrointestinal hormones in man.Digestion. 1990;46 Suppl 2:232-9. doi: 10.1159/000200391. Digestion. 1990. PMID: 2262057 Clinical Trial.
-
Cholecystokinin receptor antagonist loxiglumide modulates plasma levels of gastro-entero-pancreatic hormones in man. Feedback control of cholecystokinin and gastrin secretion.Eur J Clin Invest. 1991 Oct;21(5):501-11. doi: 10.1111/j.1365-2362.1991.tb01402.x. Eur J Clin Invest. 1991. PMID: 1752290 Clinical Trial.
-
Effects of CCK on pancreatic function and morphology.Ann N Y Acad Sci. 1994 Mar 23;713:180-98. doi: 10.1111/j.1749-6632.1994.tb44065.x. Ann N Y Acad Sci. 1994. PMID: 8185159 Review.
Cited by
-
Role of endogenous bile on basal and postprandial CCK release in humans.Dig Dis Sci. 1993 Jul;38(7):1284-90. doi: 10.1007/BF01296080. Dig Dis Sci. 1993. PMID: 8391974